The maker of analgesic OxyContin will stop promoting opioid drugs to doctors and will slash its sales army by half, a decision that follows the company receiving a barrage of lawsuits that quote the ongoing opioid epidemic.

Drug manufacturer Purdue Pharma, in a statement released on Saturday, said its remaining 200 sales representative will no longer visit doctors’ offices to advertise the highly addictive painkillers.

“We have restructured and significantly reduced our commercial operation and ceases to be promoting opioids to prescribers, ” the Connecticut-based company said in a statement obtained by Reuters .

George Frey/ Reuters Purdue Pharma, which fabricates the prescription painkiller OxyContin, has said that it will no longer be promoting opioids at doctors’ offices.

The decision comes after states, cities and counties filed suits against Purdue Pharma and other corporations, accusing them of fueling the opioid epidemic by favoring gains over human health.

Opioids, including prescription opioids, heroin and fentanyl, killed more than 42,000 people in 2016, the highest death toll ever recorded, in agreement with the Centers for Disease Control and Prevention .

Nearly half of those demises, at around 40 percent, involved a prescription opioid, the CDC said.

OxyContin, Purdue Pharma’s biggest-selling drug, generated the company $1.8 billion in 2017 — down from $2.8 billion five years earlier, Bloomberg reported quoting market researcher Symphony Health Solutions.

Purdue Pharma has defended its business practices, underlining the fact that the U.S. Food and Drug Administration approved its drugs, which account for only 2 percent of all opioid prescriptions.